Skip to content

Motor and Cognitive Functions in Acquired and Developmental Brain Damaged Patients

Studies of the Diagnosis, Rehabilitation and Links Between Motor and Cognitive Functions in Acquired and Developmental Brain Damaged Patients

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02543424
Enrollment
400
Registered
2015-09-07
Start date
2015-04-01
Completion date
2028-12-01
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebral Palsy, Hemiparesis, Perceptual Disorders

Brief summary

Neurological pathologies cause important and permanent disabilities in every day life. These pathologies can follow stoke, affecting two people per one thousand each year or cerebral palsy, affecting two births per one thousand each year. To date, the diagnosis and the rehabilitation of motor and cognitive problems has been carried out separately by different domains. For example, physiotherapists have focused on motor problems and neuropsychologists have focused on cognitive functions. However, a number of studies have demonstrated a link between motor and cognitive abilities in adults and children. The present study has three main aims: (1) to better evaluate motor and cognitive problems in brain damaged patients (all ages), (2) to understand the link between motor and cognitive abilities in patients and healthy participants and, (3) to propose new types of therapies based on the link between motor and cognitive functions.

Interventions

BEHAVIORALMotor, cognitive and neuropsychological assessment

Cognitive and motor testing and/or experimental cognitive or motor changes and/or cognitive or motor rehabilitation depending on part of the study investigated.

Sponsors

Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
5 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Congenital cerebral palsy and acquired brain injury children and adult patients * Presenting upper limb paresis and/or hemineglect * Between the age of 3 to 90. * Able to understand and carry out simple verbal instruction

Exclusion criteria

* IQ \< 70 * Severe aphasia, attentional disorder or psychiatric disorders * Neurodegenerative disorders

Design outcomes

Primary

MeasureTime frameDescription
KinematicsChange from Baseline (T0) in kinematics at an expected average of 1 week (T1), 2 months (T2) and 3 months (T3).Kinematics will be measured with a robotic tool called the REAplan. This tool is a distal effector robotic device that enables the patients to perform upper limb movements in a horizontal plane. The robot comprises a distal effector, a visual interface for the patient and a visual interface for the experimenter. It is fitted with incremental position sensors allowing the record of the distal effector's trajectory in the X and Y plane as function of time (125 Hz). From these records, all kind of quantitative and objective indices of upper limb quality of movement can be computed. Motor and cognitive tasks have been created on this device and have to be validated. These new tools on the robot provide a more accurate measure to better understand the participant's motor and cognitive functioning through kinematics analyses. Moreover, the robot can be used as a rehabilitative device, providing cognitive and motor assistance for specific exercises depending on participant performance.

Secondary

MeasureTime frameDescription
Standardized cognitive and motor assessmentChange from Baseline (T0) in cognitive and motor assessment at an expected average of 1 week (T1), 2 months (T2) and 3 months (T3).Cognition and motor performance will be also measured with standardized paper and pencil tests, scales and questionnaires using the three dimensions of the International Classification of Functioning (Body structure and function / Activity limitation / Participation restriction).

Countries

Belgium

Contacts

CONTACTMarie Alsamour
marie.alsamour@uclouvain.be
CONTACTStéphanie Dehem
stephanie.dehem@uclouvain.be
PRINCIPAL_INVESTIGATORThierry Lejeune

St. Luc Hospital

PRINCIPAL_INVESTIGATORGaëtan Stoquart

St. Luc Hospital

PRINCIPAL_INVESTIGATORMartin Edwards

Université Catholique de Louvain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 28, 2026